SEARCH

SEARCH BY CITATION

References

  • 1
    Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome : present state and perspectives. Microbiology2010; 156: 320515.
  • 2
    Pimentel M, Lembo A, Chey WD et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med2011; 364: 2232.
  • 3
    Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am2011; 40: 20722.
  • 4
    Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol2010; 7: 50314.
  • 5
    Marteau P. Probiotics in functional intestinal disorders and IBS: proof of action and dissecting the multiple mechanisms. Gut2010; 59: 2856.
  • 6
    Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut2010; 59: 32532.
  • 7
    Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther2012; 35: 40313.
  • 8
    Ringel-Kulka T, Palsson OS, Maier D et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol2011; 45: 51825.
  • 9
    Guglielmetti S, Mora D, Gschwender M et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther2011; 33: 112332.
  • 10
    Simrén M, Öhman L, Olsson J et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – a randomized, double-blind, controlled study. Aliment Pharmacol Ther2010; 31: 21827.
  • 11
    Søndergaard B, Olsson J, Ohlson K et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol2011; 46: 66372.
  • 12
    Fernandez EM, Valenti V, Rockel C et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut2011; 60: 10509.
  • 13
    Shanahan F. Molecular mechanisms of probiotic action: it’s all in the strains!Gut2011; 60: 10267.
  • 14
    Frexinos J, Denis P, Allemand H et al. Descriptive study of digestive functional symptoms in the French general population. Gastroenterol Clin Biol1998; 22: 78591.
  • 15
    Janssen HA, Borghouts JA, Muris JW et al. Health status and management of chronic non-specific abdominal complaints in general practice. Br J Gen Pract2000; 50: 3759.
  • 16
    van Kerkhoven LA, Eikendal T, Laheij RJ et al. Gastrointestinal symptoms are still common in a general Western population. Neth J Med2008; 66: 1822.
  • 17
    Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil2008; 20(Suppl 1): 1219.
  • 18
    Guyonnet D, Schlumberger A, Mhamdi L et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms. A randomised, double-blind, parallel, controlled study. Br J Nut2009; 102: 165462.
  • 19
    Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther2009; 29: 10414.
  • 20
    Guyonnet D, Chassany O, Ducrotté P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther2007; 26: 47586.
  • 21
    Marteau P, Cuillerier E, Méance S et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther2002; 16: 58793.
  • 22
    Guyonnet D, Woodcock A, Stefani B et al. Fermented milk containing Bifidobacterium animalis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J Dig Dis2009; 10: 6170.
  • 23
    Kalliomäki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet2001; 357: 10769.
  • 24
    Kopp MV, Hennemuth I, Heinzmann A et al. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics2008; 121: e8506.
  • 25
    Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 (updated September 2008). The Cochrane Collaboration 2008. Available at: http://www.cochrane-handbook.org
  • 26
    Heaton KW, O’Donnell LJ, Braddon FE et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and non consulters. Gastroenterology1992; 102: 19627.
  • 27
    Guyonnet D, Chassany O, Picard C et al. Perceived subject outcomes and impact on health-related quality of life associated with diet using the new Food Benefits Assessment (FBA©) questionnaire: development and psychometric validation. Public Health Nutr2008; 11: 116372.
  • 28
    Guyonnet D, Naliboff BD, Rondeau P, Mayer EA, Chassany O. Gastrointestinal well-being in subjects reporting mild gastrointestinal discomfort: characteristics and properties of a global assessment measure. AGA abstracts. Gastroenterology2012; 142: S8178.
  • 29
    Guidance for Industry Irritable Bowel Syndrome – Clinical Evaluation of Drugs for Treatment. Draft guidance. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. May 2012.
  • 30
    Committee for Proprietary Medicinal Products (CPMP). Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97. London, final document, March 19 2003.
  • 31
    Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology2006; 130: 153851.
  • 32
    Biró G, Hulshof KF, Ovesen L et al. Selection of methodology to assess food intake. Eur J Clin Nutr2002; 56(Suppl 2): S2532.
  • 33
    Craig CL, Marshall AL, Sjöström M et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc2003; 35: 138195.
  • 34
    Committee for Proprietary Medicinal Products (CPMP). Statistical Principles for Clinical Trials (ICH Topic E 9). CPMP/ICH/363/96. European Medicines Agency, London, 1998
  • 35
    McCullagh P. Regression models for ordinal data. J R Statist Soc B1980; 42: 10942.
  • 36
    Agresti A. Categorical Data Analysis. 2nd edn. Hoboken, New Jersey: John Wiley & Sons, Inc., 2002.
  • 37
    Altman DG. Confidence intervals for the number needed to treat. BMJ1998; 317: 130912.
  • 38
    Whitehead A. Meta-analysis using individual patient data. In: Meta-Analysis of Controlled Clinical Trials. (Statistics in Practice). Chichester; New York: John Wiley & Sons, 2002.
  • 39
    Corazziari E, Bytzer P, Delvaux M et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther2003; 18: 56980.
  • 40
    Hoveyda N, Heneghan C, Mahatani KR et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol2009; 9: 15.
  • 41
    Nakamura N, Lin HC, McSweeney CS et al. Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annu Rev Food Sci Technol2010; 1: 36395.
  • 42
    Cherbut C. Motor effects of short-chain fatty acids and lactate in the gastrointestinal tract. Proc Nut Soc2003; 62: 959.
  • 43
    Veiga P, Gallini CA, Beal C et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci USA2010; 107: 181327.
  • 44
    Kellow JE, Azpiroz F, Delvaux M et al. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology2006; 130: 141220.
  • 45
    Agostini S, Goubern M, Tondereau V et al. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil2012; 24: 376e172. (doi: 10.1111/j.1365-2982.2011.01865.x).
  • 46
    McNulty NP, Yatsunenko T, Hsiao A et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med2011; 3: 106ra106.
  • 47
    Jalanka-Tuovinen J, Salonen A, Nikkilä J et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE2011; 6: e23035.